We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Janssen, Pharmacyclics File Imbruvica sNDA for Front-line CLL
Janssen, Pharmacyclics File Imbruvica sNDA for Front-line CLL
Janssen and Pharmacyclics have submitted an sNDA for Imbruvica for front-line treatment for chronic lymphocytic leukemia, which, if approved, would provide patients who have not been treated with an alternative to chemotherapy.